Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitu
- PDF / 437,841 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 63 Downloads / 143 Views
BRIEF REPORT
Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan Ryoichi Ishibashi
. Yusuke Baba . Kyoka Kakinuma .
Atsushi Takasaki . Chihiro Hiraga . Tomomi Harama . Tetsuya Yamamoto . Susumu Nakamura . Masaya Koshizaka . Yoshiro Maezawa . Daigaku Uchida . Fumitaka Okajima
Received: October 16, 2020 / Accepted: November 13, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: In Japan, several sodium glucose co-transporter 2 (SGLT2) inhibitors have been used for type 1 diabetes mellitus as an adjuvant therapy to insulin therapy; however, there are no clinical reports regarding the satisfaction of its use. Therefore, we conducted a survey among patients with type 1 diabetes undergoing treatment using an SGLT2 inhibitor. Methods: This is a single-arm open-label prospective study including 24 patients with
R. Ishibashi (&) Y. Baba K. Kakinuma A. Takasaki C. Hiraga T. Harama T. Yamamoto S. Nakamura D. Uchida Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan e-mail: [email protected] R. Ishibashi M. Koshizaka Y. Maezawa Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan M. Koshizaka Y. Maezawa Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan F. Okajima Department of Diabetes, Endocrinology and Metabolism, Nippon Medical School, Chiba Hokusoh Hospital, Inzai, Chiba, Japan
type 1 diabetes who were to be initiated on ipragliflozin treatment between March and August 2019. All participants provided written informed consent. They completed the Diabetes Treatment Satisfaction Questionnaire (DTSQ) for the survey and 3 months of observation after the administration of an SGLT2 inhibitor (50 mg of ipragliflozin), and changes from baseline diabetes treatment satisfaction were evaluated using modified DTSQ scores (five-step evaluation) and were analyzed. Results: The average score for each question on DTSQ significantly increased [mean (standard deviation); 0.25 (0.25) vs 0.83 (0.77), P = 0.004]. Approximately 75% of the patients perceived an improvement in glycemic control over short periods of time. Finally, 54.2% of patients were highly satisfied and would recommend the SGLT2 inhibitor treatment [0.0 (0.0) vs. 0.92 (1.32), P \ 0.001]. After the administration of ipragliflozin, reductions in body weight [24.0 (2.9) vs. 23.4 (2.9) kg/m2, P = 0.002], total insulin [39.1 (12.9) vs. 34.3 (12.5) units, P = 0.013], and glycated hemoglobin [7.77 (0.97) vs. 7.40 (0.86) %, P = 0.013] were observed, without any severe side effects. Improvements in glycemic variability indexes were observed through flash glucose monitoring. Conclusions: SGLT2 inhibitors may improve clinical treatment satisfaction by improving
Diabetes Ther
glycemic variability in patients with type 1 diabetes mellitus, while not inducing severe side effects with ca
Data Loading...
